Basic Information
| LncRNA/CircRNA Name | HOXD-AS1 |
| Synonyms | HAGLR, HOXD-AS1, Mdgt |
| Region | GRCh38_2:176164051-176188958 |
| Ensemble | ENSG00000224189 |
| Refseq | NR_033979 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | papillary thyroid cancer |
| ICD-0-3 | NA |
| Methods | qPCR, other |
| Sample | PTC tissues and cell lines (K1, TPC-1, GLAG-66, BCPAP) |
| Expression Pattern | up-regulated |
| Function Description | High expression of HOXD-AS1 was associated with elderly people, advanced clinical stage, large tumor size, present lymph node metastasis, and distant metastasis. There was no significant correlation between HOXD-AS1 expression and disease-free survival or overall survival in this cohort from the TCGA database. The study in vitro suggested reduced HOXD-AS1 expression inhibited papillary thyroid cancer cell proliferation, migration, and invasion, and promoted cell-cycle arrest. |
| Pubmed ID | 30317670 |
| Year | 2019 |
| Title | HOXD-AS1 Is a Predictor of Clinical Progression and Functions as an Oncogenic lncRNAs in Papillary Thyroid Cancer |
External Links
| Links for HOXD-AS1 | GenBank HGNC NONCODE |
| Links for papillary thyroid cancer | OMIM COSMIC |